[Federal Register Volume 80, Number 175 (Thursday, September 10, 2015)]
[Notices]
[Pages 54571-54572]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-22771]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of a Start-up Exclusive Option License: 
Therapeutic Uses for Cardio-Metabolic Indications, Including 
Hypertriglyceridemia, Hypercholesterolemia and Diabetes

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health (NIH), Department of 
Health and Human Services, is contemplating the grant of a

[[Page 54572]]

Start-Up Exclusive Option License to practice the invention embodied in 
Patent Applications USSN 61/045,213, filed April 15, 2008; PCT/US2009/
040560, filed April 14, 2009; and US 12/937,974, filed October 14, 
2010, issued as 8,936,787 on January 20, 2015; titled ``Peptides 
Promoting Lipid Efflux'' (NIH Ref. E-138-2008/0) to Corvidia 
Corporation, having a place of business in Boston, MA. The patent 
rights in this invention have been assigned to the United States of 
America.

DATES: Only written comments and/or application for a license that are 
received by the NIH Office of Technology Transfer on or before 
September 25, 2015 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A., 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Email: 
[email protected]; Telephone: 301-435-4507; Facsimile: 301-402-
0220.

SUPPLEMENTARY INFORMATION: The invention relates to compositions and 
methods for using multi-domain amphipathic [alpha]-helical peptides or 
peptide analogs to treat or inhibit dyslipidemic disorders. More 
specifically, the peptides and peptide analogs with multiple 
amphipathic [alpha]-helical domains: (a) Promote lipid efflux from 
cells via an ABCAl-dependent pathway; and (b) activate lipoprotein 
lipase.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive option license may be granted unless, 
within 15 days from the date of this published Notice, NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR part 404.
    The field of use may be limited to ``Therapeutic uses for cardio-
metabolic indications, including hypertriglyceridemia, 
hypercholesterolemia and diabetes''.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: September 3, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-22771 Filed 9-9-15; 8:45 am]
BILLING CODE 4140-01-P